Article
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Environmental health perspectives - 1 Nov 1992
Caporaso N E, Shields P G, Landi M T, Shaw G L, Tucker M A, Hoover R, Sugimura H, Weston A, Harris C C
Abstract excerpt
Debrisoquine is an antihypertensive drug that is metabolized by cytochrome P4502D6. Deficient metabolism is inherited as an autosomal recessive condition. We previously reported in a case-control study that extensive metabolizers of debrisoquine were at greater risk of lung cancer compared to poor and intermediate metabolizers. Cloning of the gene that encodes P4502D6 (CYP2D6) led to the identification of both...
Topics
- Case-Control Studies
- Debrisoquin
- Genotype
- Humans
- Lung Neoplasms
- Phenotype
- Polymerase Chain Reaction
- Polymorphism, Restriction Fragment Length
- Risk Factors